Resveratrol Protects Nerves and Calms Pain Signaling in Mice With Chemotherapy Neuropathy
In paclitaxel-treated mice, resveratrol cut oxidative stress, restored AMPK-PGC-1α signaling, preserved nerve structure and reduced pain hypersensitivity.
Summary
Chemotherapy-induced peripheral neuropathy (CIPN) causes lasting numbness, tingling and pain, and no treatment currently changes its course. This mouse study tested resveratrol, a plant polyphenol, after paclitaxel chemotherapy. Treatment began a week after the drug and ran daily for about a week. Resveratrol reduced touch hypersensitivity. In the sensory nerve cell clusters (dorsal root ganglia), it lowered a marker of oxidative stress and restored an energy-sensing pathway (AMPK-PGC-1α) and the mitochondrial antioxidant enzyme SOD2. It also helped preserve nerve structure: myelin proteins recovered, sural nerve ultrastructure improved, and loss of the small nerve fibers in skin was reduced. Imaging showed less abnormal overexcitability of sensory neurons. This is a mouse model with an abstract-level report, so it shows mechanism and function, not human benefit. Lifespan was not studied, and nothing here shows that resveratrol works in people receiving chemotherapy.
Detailed Summary
Chemotherapy-induced peripheral neuropathy (CIPN) is a dose-limiting side effect of drugs such as paclitaxel. It leaves many cancer survivors with persistent sensory loss and chronic pain, and no disease-modifying therapy exists. Because oxidative stress, mitochondrial dysfunction and nerve fiber loss are thought to drive the damage, it is also a model of how nerves degrade under metabolic stress, a theme that overlaps with aging biology.
The researchers gave mice paclitaxel to induce CIPN, then administered resveratrol daily from post-injection day 7 to 13, meaning treatment started after neuropathy was developing. They combined behavioral testing of hypersensitivity, redox measurements, molecular and electrophysiological work in dorsal root ganglia (DRG), electron microscopy of sural nerves, and counts of intraepidermal nerve fibers in plantar skin.
On function, resveratrol significantly reduced mechanical hypersensitivity. On mechanism, it lowered DHE fluorescence, a marker of oxidative stress, in the DRG, and restored AMPK-PGC-1α signaling and expression of SOD2, a mitochondrial antioxidant enzyme. On structure, myelin protein levels recovered, sural nerve ultrastructure improved, and degeneration of skin nerve fibers was attenuated. Voltage-sensitive dye imaging showed that resveratrol dampened abnormal stimulus-evoked hyperexcitability in the DRG.
Together, the results link a redox and mitochondrial mechanism to both nerve structure and pain-related function. The authors suggest resveratrol may help with established CIPN, since dosing began after injury onset. For readers, the mechanism is worth watching: AMPK-PGC-1α activation and mitochondrial protection are central longevity pathways, and this shows them acting in peripheral nerves.
Caveats are important. This is a mouse study of one chemotherapy agent, and the summary rests on the abstract alone, so sample sizes, dose, sex of animals and statistics are unknown. Treatment was short, and durability was not reported. Whether resveratrol interferes with chemotherapy's anticancer effect was not addressed in the abstract. Lifespan was not assessed, and human efficacy remains untested.
Key Findings
- Mouse model of paclitaxel CIPN: daily resveratrol (post-injection days 7-13) significantly attenuated mechanical hypersensitivity, a functional pain-related outcome.
- Mechanism: resveratrol reduced DRG oxidative stress (DHE fluorescence) and restored AMPK-PGC-1α signaling and SOD2 expression.
- Structure: myelin proteins recovered, sural nerve ultrastructure improved, and intraepidermal nerve fiber degeneration was attenuated.
- Voltage-sensitive dye imaging showed reduced stimulus-evoked hyperexcitability in DRG neurons.
- No lifespan outcome was reported, and no human data or harms were described in the abstract.
Methodology
Preclinical mouse study of paclitaxel-induced CIPN with resveratrol given daily from post-injection day 7 to 13. Endpoints spanned behavior, redox assays, molecular and electrophysiological DRG analysis, sural nerve electron microscopy and skin nerve fiber quantification. Group sizes, dose and statistics were not available in the abstract.
Study Limitations
The summary is based on the abstract only, so design details, sample sizes, dose, sex of animals and effect sizes could not be assessed. It is a single mouse model with one chemotherapy drug and short treatment, with no human or lifespan data, and no reported assessment of effects on anticancer efficacy. Resveratrol's low bioavailability may limit translation.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.
Enter your email to subscribe:
